Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | Director · CEO CFO | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,944,690 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,227,384 · Balance 3,356,672 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Row 2 · 2026-10-06 · Tax withholding · Disposed 1,411,982 · Balance 1,944,690 F2: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,119,600 |
Reported balance
After 2026-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-06 · Exercise / conversion · Disposed 3,059,800 · Balance 6,119,600 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,508,249 |
Reported balance
After 2026-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-06 · Exercise / conversion · Disposed 167,584 · Balance 1,508,249 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy FCW Investments, LLC | 88,451 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 88,451 F3: The Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs.
F3: The Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
F6: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 167,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046201 · ownership.xml · derivative · entry 5 Finley John David · CIK 0001851034 · Director · CEO CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,508,249 Underlying: Common Stock · 167,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F6 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 3,059,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046201 · ownership.xml · derivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,119,600 Underlying: Common Stock · 3,059,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F5 · derivative.expiration_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock | 1,411,982 | $1.49 | $2,103,853.18 |
DisclosureSEC source: 0001493152-26-046201 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,944,690 F2 · kind: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 3,227,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-046201 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,356,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:26 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GiftCommon Stock | 88,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-039746 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By FCW Investments, LLC Disclosed balance after: 88,451 F1 · kind: The Reporting Person transferred these shares to FCW Investments, LLC. The Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:26 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GiftCommon Stock | 88,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-039746 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,288 F1 · kind: The Reporting Person transferred these shares to FCW Investments, LLC. The Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 22:49 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionSeries 2 Common Stock Purchase Warrant · Derivative | 133 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001493152-26-032559 · ownership.xml · derivative · entry 6 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133 shares Expires 2027-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: As adjusted in accordance with the terms of the Series 2 Common Stock Purchase Warrants following the public offering that closed on October 2, 2025. F9 · shares: Reflects adjustments pursuant to the Issuer's 1-for-50 reverse stock split effective November 15, 2022, and the Issuer's 1-for-15 reverse stock split effective April 5, 2024. F10 · derivative.exercise_date: Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants became exercisable upon receipt of stockholder approval per Nasdaq rules, which was obtained on October 6, 2022. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 22:49 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 133 | $0.70 | $93.10 |
DisclosureSEC source: 0001493152-26-032559 · ownership.xml · nonDerivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 22:49 UTC | PALISADE BIO, INC. PALI · Entity 5803 | SaleCommon Stock | 146,798 | $2.07 | $303,343.39 |
DisclosureSEC source: 0001493152-26-032559 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,555 F3 · kind: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 22:49 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 335,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-032559 · ownership.xml · derivative · entry 5 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675,833 Underlying: Common Stock · 335,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F7 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 22:49 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 335,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-032559 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. F2 · balance_after: Includes 1,899 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026. In addition, the amount of securities beneficially owned was reduced by 66 shares due to an administrative error in the total reported in the Form 4 filed February 13, 2026. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 01:07 UTC | PALISADE BIO, INC. PALI · Entity 5803 | SaleCommon Stock | 3,896 | $1.75 | $6,818.00 |
DisclosureSEC source: 0001493152-26-006831 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,353 F3 · kind: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 01:07 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006831 · ownership.xml · derivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F6 · derivative.expiration_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 01:07 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-006831 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. F2 · balance_after: Includes 4,444 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:32 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 2,011,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006255 · ownership.xml · derivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,011,000 Underlying: Common Stock · 2,011,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:39 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 9,179,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-017475 · ownership.xml · derivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,179,400 Underlying: Common Stock · 9,179,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 13:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantPhantom Units · Derivative | 323,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-012690 · ownership.xml · derivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,400 Underlying: Common Stock · 323,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.exercise_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. F2 · derivative.expiration_date: The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.expiration_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-006498 · ownership.xml · derivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001493152-25-006498 · ownership.xml · derivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in twelve equal quarterly installments over a three-year period beginning on May 11, 2025, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 2,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · derivative · entry 10 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · security: This restricted stock unit was granted on November 21, 2023, and all remaining 2,111 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F11 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023, and all remaining 2,111 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F11 · price: This restricted stock unit was granted on November 21, 2023, and all remaining 2,111 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F8 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F8 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 3,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · derivative · entry 9 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: This restricted stock unit was granted on June 11, 2023, and all remaining 3,335 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F10 · derivative.exercise_price: This restricted stock unit was granted on June 11, 2023, and all remaining 3,335 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F10 · price: This restricted stock unit was granted on June 11, 2023, and all remaining 3,335 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F8 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F8 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 1,622 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · derivative · entry 8 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,622 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: This restricted stock unit was granted on June 8, 2023, and all remaining 1,622 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F9 · derivative.exercise_price: This restricted stock unit was granted on June 8, 2023, and all remaining 1,622 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F9 · price: This restricted stock unit was granted on June 8, 2023, and all remaining 1,622 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F8 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F8 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 607 | $4.76 | $2,889.32 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 6 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,472 F6 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 5. F6 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 5. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 5 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F5 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F5 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 959 | $4.76 | $4,564.84 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,968 F4 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. F4 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 3,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F3 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F3 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 467 | $4.76 | $2,222.92 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,592 F2 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. F2 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-022037 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. Read SEC document |
| May 24, 2024 Filed May 28, 2024 10:02 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock, par value $0.01 | 1,000 | $4.81 | $4,810.00 |
DisclosureSEC source: 0001493152-24-021431 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,437 F1 · security: Reporting Person purchased 1,000 shares of Common Stock of Issuer at a price per share of $4.81 on May 24, 2024. F1 · shares: Reporting Person purchased 1,000 shares of Common Stock of Issuer at a price per share of $4.81 on May 24, 2024. F1 · price: Reporting Person purchased 1,000 shares of Common Stock of Issuer at a price per share of $4.81 on May 24, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:52 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock, par value $0.01 | 666 | $4.97 | $3,311.69 |
DisclosureSEC source: 0001493152-24-021045 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,437 F1 · security: Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from November 21, 2023 through May 20, 2024. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on May 20, 2024. F1 · shares: Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from November 21, 2023 through May 20, 2024. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on May 20, 2024. F1 · price: Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from November 21, 2023 through May 20, 2024. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on May 20, 2024. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · derivative · entry 7 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,111 Underlying: Common Stock · 211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: This restricted stock unit was granted on November 21, 2023, and 211 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,111 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F8 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023, and 211 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,111 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F8 · price: This restricted stock unit was granted on November 21, 2023, and 211 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,111 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F6 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · derivative · entry 6 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,622 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: This restricted stock unit was granted on June 8, 2023, and 232 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,622 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F7 · derivative.exercise_price: This restricted stock unit was granted on June 8, 2023, and 232 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,622 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F7 · price: This restricted stock unit was granted on June 8, 2023, and 232 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,622 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F6 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 61 | $8.46 | $516.06 |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · nonDerivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,771 F4 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. F4 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · nonDerivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 67 | $8.46 | $566.82 |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,621 F2 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. F2 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:36 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-018282 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 8, 2023. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:29 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 5,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-009709 · ownership.xml · derivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,025 Underlying: Common Stock · 5,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This restricted stock unit was granted on June 11, 2023, and 5,558 restricted stock units subject to the award vested on March 11, 2024, and an additional 50,025 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · derivative.exercise_price: This restricted stock unit was granted on June 11, 2023, and 5,558 restricted stock units subject to the award vested on March 11, 2024, and an additional 50,025 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · price: This restricted stock unit was granted on June 11, 2023, and 5,558 restricted stock units subject to the award vested on March 11, 2024, and an additional 50,025 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:29 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 5,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-009709 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 13:30 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock, par value $0.01 | 10,000 | $0.47 | $4,692.00 |
DisclosureSEC source: 0001493152-24-005207 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,649 F1 · security: Reporting Person purchased 10,000 shares of Common Stock in open market purchase transactions ranging from $0.46 to $0.47. The Reporting Person agrees to provide full information regarding the number of shares purchased at each separate price paid if requested by the SEC Staff, the Company, or a security holder of the Company. F1 · shares: Reporting Person purchased 10,000 shares of Common Stock in open market purchase transactions ranging from $0.46 to $0.47. The Reporting Person agrees to provide full information regarding the number of shares purchased at each separate price paid if requested by the SEC Staff, the Company, or a security holder of the Company. F1 · price: Reporting Person purchased 10,000 shares of Common Stock in open market purchase transactions ranging from $0.46 to $0.47. The Reporting Person agrees to provide full information regarding the number of shares purchased at each separate price paid if requested by the SEC Staff, the Company, or a security holder of the Company. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 3,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005480 · ownership.xml · derivative · entry 5 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,833 Underlying: Common Stock · 3,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: This restricted stock unit was granted on November 21, 2023 and 3,167 restricted stock units subject to the award vested on February 6, 2024 and an additional 34,833 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023 and 3,167 restricted stock units subject to the award vested on February 6, 2024 and an additional 34,833 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · price: This restricted stock unit was granted on November 21, 2023 and 3,167 restricted stock units subject to the award vested on February 6, 2024 and an additional 34,833 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 3,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005480 · ownership.xml · derivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,800 Underlying: Common Stock · 3,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This restricted stock unit was granted on February 6, 2023, and 3,475 restricted stock units subject to the award vested on February 6, 2024, and an additional 27,800 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · derivative.exercise_price: This restricted stock unit was granted on February 6, 2023, and 3,475 restricted stock units subject to the award vested on February 6, 2024, and an additional 27,800 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · price: This restricted stock unit was granted on February 6, 2023, and 3,475 restricted stock units subject to the award vested on February 6, 2024, and an additional 27,800 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005480 · ownership.xml · nonDerivative · entry 2 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F2 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F2 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 3,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005480 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on February 6, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on February 6, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on February 6, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 13:30 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock, par value $0.01 | 10,000 | $0.56 | $5,590.00 |
DisclosureSEC source: 0001493152-24-004566 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,649 F1 · security: Reporting Person purchased 10,000 shares of Common Stock at a price per share of $0.559. F1 · shares: Reporting Person purchased 10,000 shares of Common Stock at a price per share of $0.559. F1 · price: Reporting Person purchased 10,000 shares of Common Stock at a price per share of $0.559. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 1,309 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-001394 · ownership.xml · derivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: This restricted stock unit was granted on January 3, 2023 and 1,309 restricted stock units subject to the award vested on January 3, 2024. There are no additional restricted stock units underlying this grant. F3 · derivative.expiration_date: This restricted stock unit was granted on January 3, 2023 and 1,309 restricted stock units subject to the award vested on January 3, 2024. There are no additional restricted stock units underlying this grant. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 1,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-001394 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. Read SEC document |
| December 11, 2023 Filed Dec 19, 2023 22:57 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 5,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-045474 · ownership.xml · derivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,583 Underlying: Common Stock · 5,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: This restricted stock unit was granted on June 11, 2023, and 5,559 restricted stock units subject to the award vested on December 11, 2023, and an additional 55,583 restricted stock units will vest in equal quarterly installments over the remaining three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F3 · derivative.expiration_date: This restricted stock unit was granted on June 11, 2023, and 5,559 restricted stock units subject to the award vested on December 11, 2023, and an additional 55,583 restricted stock units will vest in equal quarterly installments over the remaining three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. Read SEC document |
| December 11, 2023 Filed Dec 19, 2023 22:57 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 5,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-045474 · ownership.xml · nonDerivative · entry 1 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042663 · ownership.xml · derivative · entry 4 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-11-21 F3 · security: The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. F7 · security: Each option represents the right to purchase one share of common stock at the exercise price. F8 · security: The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. F8 · derivative.exercise_date: The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042663 · ownership.xml · derivative · entry 3 Finley John David · CIK 0001851034 · Director · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires not disclosed F3 · security: The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · security: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F5 · derivative.exercise_price: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F4 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · derivative.exercise_date: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F6 · derivative.expiration_date: N/A. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.